US2011124550A1PendingUtilityA1

Thymosin beta 4 promotes wound repair

49
Assignee: REGENERX BIOPHARMACEUTICALSPriority: Jul 30, 1998Filed: Nov 2, 2010Published: May 26, 2011
Est. expiryJul 30, 2018(expired)· nominal 20-yr term from priority
Inventors:Hynda K. KleinmanAllan L. GoldsteinKatherine M. MalindaGabriel Sosne
A61P 9/00A61P 9/10A61P 29/00A61K 45/06A61K 38/1841A61K 38/2292Y10S930/18A61K 9/0048A61P 17/02A61K 38/08
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods of treatment for treating or preventing injury to cardiovascular or heart tissue in a subject in need thereof by administering an effective amount of thymosin β4 (Tβ4) peptide.

Claims

exact text as granted — not AI-modified
1 . A method of treatment for treating or preventing injury to cardiovascular or heart tissue in a subject in need thereof, comprising administering to said subject a composition comprising an effective amount of thymosin beta 4 (Tβ4). 
     
     
         2 . The method of  claim 1  wherein said injury is due to ischemia. 
     
     
         3 . The method of  claim 2  wherein said ischemia is due to atherosclerosis. 
     
     
         4 . The method of  claim 1  wherein said subject is a mammal. 
     
     
         5 . The method of  claim 4  wherein said mammal is a human. 
     
     
         6 . The method of  claim 1  wherein said composition is administered directly to said cardiovascular or heart tissue. 
     
     
         7 . The method of  claim 1  wherein said composition is administered locally to said cardiovascular or heart tissue. 
     
     
         8 . The method of  claim 1  wherein said composition is administered systemically to said subject.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.